Seres Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Cambridge, MA
MCRB chart
What traders are saying about $MCRB
Latest postsSeres Therapeutics, Inc. news
- Seres Therapeutics Marella Thorell Resigns As Evp And CFO Effective November 15, 2026 - SEC Filing
TradingView ·
- Seres Therapeutics, Inc. Estimates – NASDAQ:MCRB
TradingView ·
- Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Yahoo Finance ·
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences
Yahoo Finance ·
- Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
Yahoo Finance ·
- Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
marketbeat.com ·
- Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
Yahoo Finance ·
- Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
Yahoo Finance ·
- We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate
Yahoo Finance ·
- Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
Yahoo Finance ·
Seres Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $789,000 | $0 | $0 | $7.1M |
| Net income | $5.7M | $136,000 | -$113.7M | -$250.2M |
| Diluted EPS | $0.64 | $0.00 | $-17.77 | $-2.31 |
| Total assets (year end) | $138.2M | $139.8M | $358.6M | $348.8M |
| Cash and equivalents (year end) | $45.8M | $30.8M | $128.0M | $163.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Seres Therapeutics, Inc.
- Ticker
- MCRB (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1609809
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
Frequently asked questions
What exchange is Seres Therapeutics, Inc. listed on?
Seres Therapeutics, Inc. trades on the Nasdaq under the ticker symbol MCRB.
What industry is Seres Therapeutics, Inc. in?
Seres Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Seres Therapeutics, Inc. headquartered?
Seres Therapeutics, Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Seres Therapeutics, Inc.'s fiscal year end?
Seres Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Seres Therapeutics, Inc. report?
Seres Therapeutics, Inc. reported $789,000 in revenue for calendar year 2025, according to its SEC filings.